Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
Feature|Videos|July 18, 2024

Streamlining Rare Disease Drug Development

The discussion explores how the principles of Operation Warp Speed can be applied to expedite rare disease therapeutic development through a new FDA pilot program aimed at streamlining the drug development process.

The conversation centered around the potential of mRNA technology for therapeutic development, with a focus on project management, meeting efficiency, and the challenges of mRNA production.

Discussion Topics

  • 00:00 - Core aspects of CMC for mRNA as a shared platform for cGMP compliance
  • 2:17 - Adapting mRNA manufacturing processes to quickly produce vaccine variants
  • 5:18 - Differences in quality and purity of mRNA products from various manufacturers
  • 6:12 - Developing guidelines to accelerate rare disease drug development, similar to Operation Warp Speed

Related to this article

Close-up of a clear IV infusion bag filled with pale yellow fluid, with a pink awareness ribbon printed on its front, against a gray background. | Image Credit: © Olga - stock.adobe.com
The European Commission has authorized Biocon’s pertuzumab biosimilar Pebrilzo as a HER2-positive breast cancer treatment, the first biosimilar cleared under EMA’s tailored clinical approach, which relies on analytical and pharmacokinetic data in place of a comparative efficacy trial. The EU biosimilar approval follows FDA approval of Pebrilzo two days earlier.
The BioPharm Brief: Cosentyx Approved in Polymyalgia Rheumatica, a Phase 3 Survival Win for an AML Vaccine, and $173 Million for In Vivo Bone Marrow Editing
FDA approves Novartis’ Cosentyx as the first anti-IL-17 biologic for polymyalgia rheumatica, SELLAS Life Sciences’ WT1-targeted peptide vaccine galinpepimut-S meets its overall survival primary endpoint in the phase 3 REGAL trial in AML, and Marrow Therapeutics launches with $173 million to develop bone marrow-targeted genetic medicines.